Symbols / AGEN $3.94 +0.77% Agenus Inc.
AGEN Chart
About
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 151.29M | Enterprise Value | 196.31M | Income | -101.00K | Sales | 114.20M | Book/sh | -7.68 | Cash/sh | 0.08 |
| Dividend Yield | — | Payout | 0.00% | Employees | 81 | IPO | — | P/E | inf | Forward P/E | -1.71 |
| PEG | 1.44 | P/S | 1.32 | P/B | -0.51 | P/C | — | EV/EBITDA | -18.59 | EV/Sales | 1.72 |
| Quick Ratio | 0.03 | Current Ratio | 0.41 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | 0.00 | EPS next Y | -2.30 |
| EPS Growth | — | Revenue Growth | 27.50% | Earnings | 2026-05-11 | ROA | -5.67% | ROE | — | ROIC | — |
| Gross Margin | 96.52% | Oper. Margin | 42.09% | Profit Margin | 0.10% | Shs Outstand | 38.40M | Shs Float | 35.62M | Short Float | 11.24% |
| Short Ratio | 8.54 | Short Interest | — | 52W High | 7.34 | 52W Low | 2.63 | Beta | 1.61 | Avg Volume | 682.86K |
| Volume | 769.80K | Target Price | $15.50 | Recom | None | Prev Close | $3.91 | Price | $3.94 | Change | 0.77% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-08-28 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-06-04 | main | Baird | Neutral → Neutral | $6 |
| 2025-06-04 | up | HC Wainwright & Co. | Neutral → Buy | $25 |
| 2025-05-13 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-05-13 | main | Baird | Neutral → Neutral | $4 |
| 2025-04-30 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-18 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-12 | main | Baird | Neutral → Neutral | $3 |
| 2025-03-12 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-22 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-29 | reit | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-11-12 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-08-14 | main | B. Riley Securities | Buy → Buy | $18 |
| 2024-07-19 | down | Jefferies | Buy → Hold | $7 |
| 2024-07-18 | down | HC Wainwright & Co. | Buy → Neutral | $9 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-05-07 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
- Some cancer patients in France get reimbursed BOT+BAL access - Stock Titan ue, 21 Apr 2026 12
- AGEN (Agenus) posts far smaller Q4 2025 loss than analyst forecasts, shares drop 7.72 percent today. - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 20
- AGEN (Agenus Inc.) Q4 2025 loss far narrower than expected, shares rise 3.23 percent in today’s session. - Community Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 15
- Is Agenus (AGEN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Mon, 20 Apr 2026 13
- Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN Sun, 19 Apr 2026 17
- Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term - Eastern Progress Fri, 17 Apr 2026 08
- Agenus (NASDAQ: AGEN) director Armen receives 3,403 fully vested shares as salary - Stock Titan ue, 21 Apr 2026 20
- Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance ue, 13 Jan 2026 08
- Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Eastern Progress Fri, 17 Apr 2026 09
- Agenus cancer drug combo kept 43% alive at 18 months in study - Stock Titan Fri, 17 Apr 2026 20
- Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance Fri, 03 Apr 2026 07
- Agenus (NASDAQ: AGEN) asks shareholders to approve 5M shares, highlights BOT+BAL data - Stock Titan Mon, 20 Apr 2026 21
- Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance Mon, 16 Mar 2026 07
- Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Finance Fri, 03 Apr 2026 07
- Agenus secures $20M to scale U.S. biologics output for BOT and BAL - Stock Titan ue, 10 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
114.20
+10.37%
|
103.46
-33.81%
|
156.31
+59.47%
|
98.02
|
| Operating Revenue |
|
5.61
+125.67%
|
2.48
-94.05%
|
41.74
-20.85%
|
52.74
|
| Cost Of Revenue |
|
80.36
-48.49%
|
156.01
-34.36%
|
237.68
+20.49%
|
197.26
|
| Reconciled Cost Of Revenue |
|
80.36
-48.49%
|
156.01
-34.36%
|
237.68
+20.49%
|
197.26
|
| Gross Profit |
|
33.84
+164.39%
|
-52.55
+35.41%
|
-81.37
+18.01%
|
-99.23
|
| Operating Expense |
|
54.39
-24.33%
|
71.88
-8.71%
|
78.74
-2.80%
|
81.01
|
| Selling General And Administration |
|
54.39
-24.33%
|
71.88
-8.71%
|
78.74
-2.80%
|
81.01
|
| General And Administrative Expense |
|
54.39
-24.33%
|
71.88
-8.71%
|
78.74
-2.80%
|
81.01
|
| Other Gand A |
|
54.39
-24.33%
|
71.88
-8.71%
|
78.74
-2.80%
|
81.01
|
| Total Expenses |
|
134.75
-40.87%
|
227.89
-27.98%
|
316.42
+13.71%
|
278.27
|
| Operating Income |
|
-20.56
+83.48%
|
-124.43
+22.28%
|
-160.10
+11.17%
|
-180.24
|
| Total Operating Income As Reported |
|
-20.17
+83.26%
|
-120.47
+24.49%
|
-159.55
+11.08%
|
-179.43
|
| EBITDA |
|
62.19
+161.39%
|
-101.30
+30.58%
|
-145.92
+9.84%
|
-161.85
|
| Normalized EBITDA |
|
-39.12
+62.83%
|
-105.26
+28.14%
|
-146.48
+8.86%
|
-160.72
|
| Reconciled Depreciation |
|
10.00
-25.06%
|
13.34
-1.80%
|
13.59
+95.62%
|
6.95
|
| EBIT |
|
52.19
+145.52%
|
-114.64
+28.13%
|
-159.51
+5.50%
|
-168.79
|
| Total Unusual Items |
|
101.31
+2462.24%
|
3.95
+611.15%
|
0.56
+149.55%
|
-1.12
|
| Total Unusual Items Excluding Goodwill |
|
101.31
+2462.24%
|
3.95
+611.15%
|
0.56
+149.55%
|
-1.12
|
| Special Income Charges |
|
101.31
+2462.24%
|
3.95
+611.15%
|
0.56
+149.55%
|
-1.12
|
| Other Special Charges |
|
—
|
—
|
—
|
1.94
|
| Restructuring And Mergern Acquisition |
|
-0.39
+90.21%
|
-3.95
-611.15%
|
-0.56
+31.78%
|
-0.81
|
| Net Income |
|
0.12
+100.05%
|
-227.21
+7.55%
|
-245.76
-11.67%
|
-220.07
|
| Pretax Income |
|
-3.08
+98.67%
|
-232.27
+9.78%
|
-257.44
-11.61%
|
-230.66
|
| Net Non Operating Interest Income Expense |
|
-55.27
+53.01%
|
-117.63
-20.12%
|
-97.92
-58.29%
|
-61.86
|
| Interest Expense Non Operating |
|
55.27
-53.01%
|
117.63
+20.12%
|
97.92
+58.29%
|
61.86
|
| Net Interest Income |
|
-55.27
+53.01%
|
-117.63
-20.12%
|
-97.92
-58.29%
|
-61.86
|
| Interest Expense |
|
55.27
-53.01%
|
117.63
+20.12%
|
97.92
+58.29%
|
61.86
|
| Other Income Expense |
|
72.75
+643.52%
|
9.78
+1549.92%
|
0.59
-94.82%
|
11.45
|
| Other Non Operating Income Expenses |
|
-2.22
-138.08%
|
5.83
+15656.76%
|
0.04
-99.71%
|
12.57
|
| Gain On Sale Of Business |
|
100.92
|
0.00
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-3.08
+98.67%
|
-232.27
+9.78%
|
-257.44
-11.61%
|
-230.66
|
| Net Income From Continuing Operation Net Minority Interest |
|
0.12
+100.05%
|
-227.21
+7.55%
|
-245.76
-11.67%
|
-220.07
|
| Net Income From Continuing And Discontinued Operation |
|
0.12
+100.05%
|
-227.21
+7.55%
|
-245.76
-11.67%
|
-220.07
|
| Net Income Continuous Operations |
|
-3.08
+98.67%
|
-232.27
+9.78%
|
-257.44
-11.61%
|
-230.66
|
| Minority Interests |
|
3.20
-36.79%
|
5.06
-56.67%
|
11.68
+10.34%
|
10.58
|
| Normalized Income |
|
-101.20
+56.22%
|
-231.17
+6.15%
|
-246.32
-12.50%
|
-218.95
|
| Net Income Common Stockholders |
|
-0.10
+99.96%
|
-227.43
+7.54%
|
-245.97
-11.66%
|
-220.29
|
| Diluted EPS |
|
—
|
-10.59
+22.98%
|
-13.75
+12.08%
|
-15.64
|
| Basic EPS |
|
—
|
-10.59
+22.98%
|
-13.75
+12.08%
|
-15.64
|
| Basic Average Shares |
|
—
|
21.47
+20.00%
|
17.89
+27.02%
|
14.09
|
| Diluted Average Shares |
|
—
|
21.47
+20.00%
|
17.89
+27.02%
|
14.09
|
| Diluted NI Availto Com Stockholders |
|
-0.10
+99.96%
|
-227.43
+7.54%
|
-245.97
-11.66%
|
-220.29
|
| Earnings From Equity Interest |
|
-26.34
|
0.00
|
0.00
|
—
|
| Preferred Stock Dividends |
|
0.22
+0.47%
|
0.21
+0.94%
|
0.21
+0.47%
|
0.21
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
226.80
+0.23%
|
226.27
-27.92%
|
313.91
-24.09%
|
413.56
|
| Current Assets |
|
133.44
+192.79%
|
45.57
-59.46%
|
112.42
-47.25%
|
213.12
|
| Cash Cash Equivalents And Short Term Investments |
|
3.00
-92.59%
|
40.44
-46.87%
|
76.11
-60.64%
|
193.36
|
| Cash And Cash Equivalents |
|
3.00
-92.59%
|
40.44
-46.87%
|
76.11
-57.40%
|
178.67
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
14.68
|
| Receivables |
|
7.01
+1622.36%
|
0.41
-98.42%
|
25.84
+842.58%
|
2.74
|
| Accounts Receivable |
|
1.83
+349.88%
|
0.41
-98.42%
|
25.84
+842.58%
|
2.74
|
| Prepaid Assets |
|
0.79
-66.09%
|
2.31
-71.41%
|
8.10
-41.44%
|
13.83
|
| Assets Held For Sale Current |
|
121.55
|
0.00
|
—
|
—
|
| Other Current Assets |
|
1.09
-54.91%
|
2.42
+1.81%
|
2.37
-25.74%
|
3.19
|
| Total Non Current Assets |
|
93.36
-48.33%
|
180.70
-10.32%
|
201.50
+0.53%
|
200.43
|
| Net PPE |
|
23.21
-84.25%
|
147.40
-9.59%
|
163.03
-0.77%
|
164.29
|
| Gross PPE |
|
70.68
-67.86%
|
219.95
-2.23%
|
224.97
+3.03%
|
218.36
|
| Accumulated Depreciation |
|
-47.47
+34.57%
|
-72.55
-17.13%
|
-61.94
-14.55%
|
-54.08
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
10.06
-18.15%
|
12.29
+0.00%
|
12.29
+0.00%
|
12.29
|
| Buildings And Improvements |
|
0.00
-100.00%
|
5.84
+0.00%
|
5.84
+3.24%
|
5.65
|
| Machinery Furniture Equipment |
|
29.22
-62.95%
|
78.87
-1.51%
|
80.08
+8.32%
|
73.93
|
| Construction In Progress |
|
0.06
-92.86%
|
0.78
-48.15%
|
1.51
-97.73%
|
66.46
|
| Other Properties |
|
7.74
-71.64%
|
27.31
-7.76%
|
29.61
-5.32%
|
31.27
|
| Leases |
|
23.61
-75.12%
|
94.86
-0.82%
|
95.64
+232.59%
|
28.76
|
| Goodwill And Other Intangible Assets |
|
27.13
-1.23%
|
27.47
-5.72%
|
29.13
-8.08%
|
31.70
|
| Goodwill |
|
24.09
+0.00%
|
24.09
-2.55%
|
24.72
-2.92%
|
25.47
|
| Other Intangible Assets |
|
3.04
-10.04%
|
3.38
-23.46%
|
4.41
-29.17%
|
6.23
|
| Investments And Advances |
|
24.28
|
0.00
|
—
|
—
|
| Long Term Equity Investment |
|
24.28
|
0.00
|
—
|
—
|
| Non Current Accounts Receivable |
|
15.44
|
—
|
—
|
—
|
| Other Non Current Assets |
|
3.31
-43.32%
|
5.83
-37.51%
|
9.34
+109.66%
|
4.45
|
| Total Liabilities Net Minority Interest |
|
504.66
-5.26%
|
532.70
+15.23%
|
462.30
-1.32%
|
468.46
|
| Current Liabilities |
|
323.49
+46.11%
|
221.40
-13.48%
|
255.90
+35.43%
|
188.95
|
| Payables And Accrued Expenses |
|
108.10
+20.55%
|
89.67
-11.63%
|
101.48
+39.63%
|
72.68
|
| Payables |
|
82.99
+35.00%
|
61.47
+0.04%
|
61.45
+50.09%
|
40.94
|
| Accounts Payable |
|
82.99
+35.00%
|
61.47
+0.04%
|
61.45
+50.09%
|
40.94
|
| Current Accrued Expenses |
|
25.12
-10.94%
|
28.20
-29.55%
|
40.03
+26.13%
|
31.74
|
| Current Debt And Capital Lease Obligation |
|
45.79
+365.07%
|
9.85
-25.35%
|
13.19
+423.83%
|
2.52
|
| Current Debt |
|
44.66
+1555.11%
|
2.70
+1747.95%
|
0.15
-74.61%
|
0.57
|
| Other Current Borrowings |
|
10.46
+309.76%
|
2.55
|
—
|
0.43
|
| Current Capital Lease Obligation |
|
1.14
-84.11%
|
7.15
-45.20%
|
13.04
+571.33%
|
1.94
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
0.03
+72.22%
|
0.02
-99.85%
|
12.27
|
| Current Deferred Revenue |
|
0.00
-100.00%
|
0.03
+72.22%
|
0.02
-99.85%
|
12.27
|
| Other Current Liabilities |
|
169.59
+39.18%
|
121.85
-13.71%
|
141.21
+39.14%
|
101.49
|
| Total Non Current Liabilities Net Minority Interest |
|
181.17
-41.80%
|
311.29
+50.82%
|
206.40
-26.16%
|
279.51
|
| Long Term Debt And Capital Lease Obligation |
|
10.11
-88.11%
|
85.02
+12.95%
|
75.28
-0.83%
|
75.91
|
| Long Term Debt |
|
—
|
30.47
+138.67%
|
12.77
+1.46%
|
12.58
|
| Long Term Capital Lease Obligation |
|
10.11
-81.47%
|
54.55
-12.73%
|
62.51
-1.29%
|
63.33
|
| Non Current Deferred Liabilities |
|
1.14
+0.00%
|
1.14
+0.00%
|
1.14
+0.00%
|
1.14
|
| Non Current Deferred Revenue |
|
1.14
+0.00%
|
1.14
+0.00%
|
1.14
+0.00%
|
1.14
|
| Other Non Current Liabilities |
|
169.92
-24.52%
|
225.13
+73.21%
|
129.98
-35.80%
|
202.45
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
-271.11
+16.93%
|
-326.38
-103.57%
|
-160.33
-161.65%
|
-61.28
|
| Common Stock Equity |
|
-271.11
+16.93%
|
-326.38
-103.57%
|
-160.33
-161.65%
|
-61.28
|
| Capital Stock |
|
0.35
+49.58%
|
0.24
+19.80%
|
0.20
-93.55%
|
3.06
|
| Common Stock |
|
0.35
+49.58%
|
0.24
+19.80%
|
0.20
-93.55%
|
3.06
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
35.32
+49.44%
|
23.63
+19.86%
|
19.72
+29.06%
|
15.28
|
| Ordinary Shares Number |
|
35.32
+49.44%
|
23.63
+19.86%
|
19.72
+29.06%
|
15.28
|
| Additional Paid In Capital |
|
1,911.74
+2.91%
|
1,857.66
+3.43%
|
1,796.10
+9.21%
|
1,644.66
|
| Retained Earnings |
|
-2,182.76
+0.01%
|
-2,182.88
-11.62%
|
-1,955.67
-14.37%
|
-1,709.91
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.44
+68.60%
|
-1.40
-46.39%
|
-0.95
-204.37%
|
0.92
|
| Treasury Stock |
|
—
|
—
|
0.00
|
0.00
|
| Minority Interest |
|
-6.75
-133.82%
|
19.96
+67.01%
|
11.95
+87.41%
|
6.38
|
| Other Equity Adjustments |
|
-0.44
+68.60%
|
-1.40
-46.39%
|
-0.95
-204.37%
|
0.92
|
| Total Equity Gross Minority Interest |
|
-277.86
+9.32%
|
-306.42
-106.51%
|
-148.38
-170.27%
|
-54.90
|
| Total Capitalization |
|
-271.11
+8.38%
|
-295.91
-100.53%
|
-147.56
-203.04%
|
-48.69
|
| Working Capital |
|
-190.05
-8.09%
|
-175.83
-22.54%
|
-143.48
-693.63%
|
24.17
|
| Invested Capital |
|
-226.46
+22.77%
|
-293.21
-98.90%
|
-147.42
-206.36%
|
-48.12
|
| Total Debt |
|
55.90
-41.08%
|
94.87
+7.24%
|
88.47
+12.80%
|
78.43
|
| Net Debt |
|
41.66
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
11.24
-81.78%
|
61.70
-18.34%
|
75.56
+15.76%
|
65.27
|
| Net Tangible Assets |
|
-298.24
+15.72%
|
-353.85
-86.76%
|
-189.47
-103.78%
|
-92.97
|
| Tangible Book Value |
|
-298.24
+15.72%
|
-353.85
-86.76%
|
-189.47
-103.78%
|
-92.97
|
| Current Notes Payable |
|
34.20
+23323.29%
|
0.15
+0.00%
|
0.15
+0.00%
|
0.15
|
| Duefrom Related Parties Non Current |
|
15.44
|
0.00
|
—
|
—
|
| Investmentsin Associatesat Cost |
|
24.28
|
0.00
|
—
|
—
|
| Notes Receivable |
|
5.18
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-77.19
+51.24%
|
-158.31
+29.39%
|
-224.20
-27.84%
|
-175.37
|
| Cash Flow From Continuing Operating Activities |
|
-77.19
+51.24%
|
-158.31
+29.39%
|
-224.20
-27.84%
|
-175.37
|
| Net Income From Continuing Operations |
|
-3.08
+98.67%
|
-232.27
+9.78%
|
-257.44
-11.61%
|
-230.66
|
| Depreciation Amortization Depletion |
|
10.00
-25.06%
|
13.34
-1.80%
|
13.59
+95.62%
|
6.95
|
| Depreciation And Amortization |
|
10.00
-25.06%
|
13.34
-1.80%
|
13.59
+95.62%
|
6.95
|
| Other Non Cash Items |
|
-51.19
-537.82%
|
11.69
+182.69%
|
-14.14
-172.12%
|
19.61
|
| Stock Based Compensation |
|
13.77
-20.82%
|
17.39
-23.96%
|
22.87
+24.72%
|
18.34
|
| Asset Impairment Charge |
|
0.23
-88.14%
|
1.97
|
0.00
-100.00%
|
6.11
|
| Operating Gains Losses |
|
-100.37
-2087.27%
|
-4.59
-133.66%
|
-1.96
+90.08%
|
-19.80
|
| Gain Loss On Investment Securities |
|
-0.39
+90.21%
|
-3.95
-611.15%
|
-0.56
+31.78%
|
-0.81
|
| Unrealized Gain Loss On Investment Securities |
|
26.12
+1593.84%
|
1.54
-27.47%
|
2.13
|
—
|
| Change In Working Capital |
|
27.33
-16.16%
|
32.60
+203.12%
|
10.76
-55.34%
|
24.08
|
| Change In Receivables |
|
-1.73
-106.82%
|
25.34
+208.03%
|
-23.46
-19330.33%
|
0.12
|
| Changes In Account Receivables |
|
-1.73
-106.82%
|
25.34
+208.03%
|
-23.46
-19330.33%
|
0.12
|
| Change In Inventory |
|
—
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
1.26
-78.21%
|
5.78
-4.14%
|
6.03
-49.16%
|
11.87
|
| Change In Payables And Accrued Expense |
|
28.00
+1202.89%
|
2.15
-94.88%
|
41.98
+392.25%
|
8.53
|
| Change In Accrued Expense |
|
4.50
+3208.09%
|
0.14
-99.34%
|
20.61
+913.42%
|
2.03
|
| Change In Payable |
|
23.50
+1067.41%
|
2.01
-90.58%
|
21.37
+229.01%
|
6.49
|
| Change In Account Payable |
|
23.50
+1067.41%
|
2.01
-90.58%
|
21.37
+229.01%
|
6.49
|
| Change In Other Working Capital |
|
-0.20
+70.64%
|
-0.67
+95.14%
|
-13.79
-486.49%
|
3.57
|
| Investing Cash Flow |
|
1.19
+4322.22%
|
0.03
-99.21%
|
3.40
+110.12%
|
-33.61
|
| Cash Flow From Continuing Investing Activities |
|
1.19
+4322.22%
|
0.03
-99.21%
|
3.40
+110.12%
|
-33.61
|
| Net PPE Purchase And Sale |
|
0.35
+163.95%
|
-0.55
+91.62%
|
-6.59
+78.78%
|
-31.06
|
| Purchase Of PPE |
|
-0.01
+98.96%
|
-0.58
+94.21%
|
-9.95
+81.24%
|
-53.06
|
| Sale Of PPE |
|
0.36
+1395.83%
|
0.02
-99.29%
|
3.36
-84.71%
|
22.00
|
| Capital Expenditure |
|
-0.01
+98.96%
|
-0.58
+94.21%
|
-9.95
+81.24%
|
-53.06
|
| Net Investment Purchase And Sale |
|
0.84
+45.25%
|
0.58
-94.20%
|
9.99
+2592.99%
|
0.37
|
| Purchase Of Investment |
|
0.00
|
0.00
+100.00%
|
-20.04
+18.62%
|
-24.63
|
| Sale Of Investment |
|
0.84
+45.25%
|
0.58
-98.07%
|
30.03
+20.14%
|
25.00
|
| Net Business Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-2.92
|
| Purchase Of Business |
|
—
|
0.00
|
0.00
+100.00%
|
-2.92
|
| Gain Loss On Sale Of Business |
|
-100.92
|
0.00
|
0.00
|
—
|
| Financing Cash Flow |
|
36.59
-70.21%
|
122.84
+2.48%
|
119.87
+25.08%
|
95.83
|
| Cash Flow From Continuing Financing Activities |
|
36.59
-70.21%
|
122.84
+2.48%
|
119.87
+25.08%
|
95.83
|
| Net Issuance Payments Of Debt |
|
2.35
-75.32%
|
9.52
+206.64%
|
-8.93
-1721.63%
|
-0.49
|
| Issuance Of Debt |
|
12.50
-37.50%
|
20.00
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-10.15
+3.15%
|
-10.48
-17.42%
|
-8.93
-1721.63%
|
-0.49
|
| Long Term Debt Issuance |
|
12.50
-37.50%
|
20.00
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-10.15
+3.15%
|
-10.48
-17.42%
|
-8.93
-1721.63%
|
-0.49
|
| Net Long Term Debt Issuance |
|
2.35
-75.32%
|
9.52
+206.64%
|
-8.93
-1721.63%
|
-0.49
|
| Net Common Stock Issuance |
|
36.05
-7.15%
|
38.82
-69.67%
|
127.98
+34.13%
|
95.42
|
| Common Stock Payments |
|
-0.09
|
0.00
+100.00%
|
-5.17
-36.50%
|
-3.79
|
| Repurchase Of Capital Stock |
|
-0.09
|
0.00
+100.00%
|
-5.17
-36.50%
|
-3.79
|
| Proceeds From Stock Option Exercised |
|
0.17
-73.88%
|
0.65
-19.83%
|
0.81
-10.13%
|
0.90
|
| Net Other Financing Charges |
|
-1.97
-102.67%
|
73.85
+12286.63%
|
-0.61
|
—
|
| Changes In Cash |
|
-39.41
-11.17%
|
-35.45
+64.88%
|
-100.94
+10.80%
|
-113.15
|
| Effect Of Exchange Rate Changes |
|
0.05
+118.08%
|
-0.26
+58.60%
|
-0.63
-503.85%
|
-0.10
|
| Beginning Cash Position |
|
44.07
-44.76%
|
79.78
-56.01%
|
181.34
-38.44%
|
294.60
|
| End Cash Position |
|
4.71
-89.31%
|
44.07
-44.76%
|
79.78
-56.01%
|
181.34
|
| Free Cash Flow |
|
-77.20
+51.41%
|
-158.89
+32.14%
|
-234.16
-2.50%
|
-228.44
|
| Interest Paid Supplemental Data |
|
1.18
-48.42%
|
2.28
-28.09%
|
3.17
+177.17%
|
1.14
|
| Common Stock Issuance |
|
36.14
-6.92%
|
38.82
-70.84%
|
133.16
+34.22%
|
99.21
|
| Issuance Of Capital Stock |
|
36.14
-6.92%
|
38.82
-70.84%
|
133.16
+34.22%
|
99.21
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-21 View
- 42026-04-13 View
- 42026-04-06 View
- 42026-04-02 View
- 8-K2026-03-26 View
- 42026-03-24 View
- 10-K2026-03-16 View
- 8-K2026-03-16 View
- 42026-03-09 View
- 42026-02-24 View
- 42026-02-09 View
- 42026-01-26 View
- 8-K2026-01-16 View
- 8-K2026-01-14 View
- 42026-01-12 View
- 8-K2026-01-08 View
- 42026-01-05 View
- 42026-01-05 View
- 42025-12-29 View
- 42025-12-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|